Fluence LED Solutions Pave the Way for Optimizing Success in Urban Medicinal Cannabis Grow
10.5.2023 15:30:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its success in supporting Trichome, an Israeli facility growing world-class medicinal cannabis, to prove the concept of two-tiered vertical farming in an urban center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005315/en/
Fluence LEDs inside Trichome's urban facility have supported 17 full crop growing cycles, all with greater than expected results. (Photo: Business Wire)
To successfully launch an urban vertical growing facility in Qiryat Gat, Israel, Trichome needed to collaborate with the right solution partners to maximize space while optimizing quality and automation at every step of the process. To appropriately design for the compact, intricate indoor environment and complexities associated with tiered growing, Trichome turned to Fluence for its market-leading LED lighting solutions, local service capabilities through Fluence's Israeli distribution partner, REMY, and in-house horticultural experts to assist with planning, installing and managing the deployment of integrated lighting technology.
“By partnering with Fluence, we were not reinventing the wheel but choosing the best wheels in the market,” said Tony Levi, co-founder and CEO of Trichome. “Standardization, longevity and optimization are critical factors in producing high-quality cannabis flowers. The team of experts at Fluence helped us accomplish all of those goals in an urban farm within city limits.”
Trichome installed Fluence lighting throughout its fully standardized medicinal cannabis facility. To overcome the obstacles presented by a reduction in space between crops and the artificial lights in vertical farms, Fluence worked closely with REMY, Levi and the Trichome team to understand the facility’s constraints. Ultimately, Fluence designed a bespoke system comprising its SPYDR 2i, SPYDR 2x and RAZR Modular series for Trichome. Trichome has completed 17 full crop growing cycles, all with greater than expected results using Fluence lighting—including above average yields, higher than expected terpene levels and high cannabinoid content.
“We are thrilled by the response of our plants to the Fluence LED lighting,” said Steve Abboud, head grower at Trichome. “Our cannabis crops are taking in the light from Fluence fixtures and expressing its quality through their flowering. We have been able to standardize light intensity, harness control over our cultivation methods and achieve crop uniformity because of Fluence LEDs.”
“Working with Trichome on lighting solutions has been an exciting and ambitious process where both parties learned a tremendous amount,” said Jörg Meyer-Brenken, lead account manager, cannabis EMEA at Fluence. “The product Trichome supplies is outstanding, but the feedback from the market and patients makes me even prouder. Trichome has been able to set a new bar for urban farming.”
Fluence LED lighting solutions are available for purchase by licensed cultivators in territories in which the cultivation of cannabis is legal.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, today, it also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
About Trichome
Trichome is an Israeli agritech company that combines two complementary worlds—quality cannabis agriculture and advanced cannabis technologies. The company philosophy is based on three main pillars: Indoor Growth by Advanced Technology, an international team of cannabis experts and the finest, high-end varieties. Trichome owns the largest Indoor facility for medical cannabis cultivation in the Middle East. With nine flowering rooms, the multilayer facility is spread over 7,000 square meters and has an annual production capacity of six tons of high-quality, consistent standardized inflorescence. Trichome works through several channels including its own brand and white label. For more information, visit www.trichome-il.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005315/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (0) 160 93335045
For North America,
Callie Neatherlin
Red Fan Communications
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
